Maple Syrup Urine Disease · MSUD

Description

Maple syrup urine disease, MSUD, is an autosomal recessive disorder of branched-chain amino acid metabolism. Pathogenic variants in BCKDHA, BCKDHB, or DBT reduce activity of the branched-chain alpha-ketoacid dehydrogenase complex. The complex normally degrades the branched-chain amino acids leucine, isoleucine, and valine. With the enzyme impaired, these amino acids and their corresponding ketoacids accumulate in blood and tissues. Leucine and its ketoacid drive the neurological injury. The characteristic maple syrup odor in cerumen and urine comes from accumulated branched-chain ketoacids.

Affected newborns with classic MSUD typically present in the first one to two weeks of life with poor feeding, lethargy, irritability, dystonia, and progressive encephalopathy. Untreated disease leads to cerebral edema, coma, and death. Older children and adults are at lifelong risk of metabolic decompensation during illness, fasting, surgery, or other catabolic stress.

Detection is by newborn screening on the dried blood spot, using tandem mass spectrometry to measure leucine. Confirmation uses plasma amino acids, urine organic acids, and gene sequencing of BCKDHA, BCKDHB, and DBT. Variant forms with residual enzyme activity, including intermediate, intermittent, and thiamine-responsive MSUD, present later and milder.

Reported worldwide birth incidence is approximately 1 in 185,000 in unselected populations. The Old Order Mennonite community in Lancaster County, Pennsylvania has a striking founder effect tied to a BCKDHA variant. Strauss et al. (American Journal of Medical Genetics, 2010) reported an incidence of approximately 1 in 380 live births in that community, the highest documented anywhere.

Treatments to date

Treatment is started as soon as MSUD is suspected after newborn screening or clinical presentation, and continues for life. Goals are to keep plasma leucine within a target range, prevent decompensation, and protect the brain.

Lifelong dietary management is the standard of care. Natural protein intake is restricted to control leucine, and a branched-chain-amino-acid-free medical formula provides the remaining protein, calories, vitamins, and minerals. Isoleucine and valine are supplemented as needed because excessive restriction depletes them. A metabolic dietitian monitors plasma amino acids, growth, and nutrient adequacy.

Acute decompensation is a medical emergency. Standard care reverses catabolism with high-calorie intravenous dextrose and intralipid, withholds branched-chain amino acid intake briefly, then reintroduces isoleucine and valine to support protein synthesis. Severe leucine elevation or cerebral edema may require hemodialysis. The Clinic for Special Children in Strasburg, Pennsylvania, founded by Holmes Morton, developed and refined many of the protocols used in the Mennonite cohort and beyond.

Liver transplantation cures the metabolic disease. The transplanted liver supplies enough functional branched-chain alpha-ketoacid dehydrogenase activity that recipients can return to a normal protein diet without leucine excursions. Mazariegos et al. (Journal of Pediatrics, 2012) reported sustained metabolic correction in a multicenter cohort following deceased-donor liver transplantation. Transplant carries the lifelong burden of immunosuppression, and decisions are individualized.

Thiamine supplementation is used in the small subset with thiamine-responsive variants, who carry residual enzyme activity that improves with high-dose thiamine.

No FDA-approved disease-specific drug exists for MSUD. Investigational approaches include hepatocyte transplantation, AAV-delivered gene therapy, and mRNA therapeutics; all remain confined to early-stage studies.